Literature DB >> 16641207

Developmental regulation of GTP-CH1 in the porcine lung and its relationship to pulmonary vascular relaxation.

Manasi Nandi1, James Leiper, Francesca Arrigoni, Alison Hislop, Patrick Vallance, Sheila Haworth.   

Abstract

Nitric oxide (NO) plays an important role in lowering pulmonary vascular resistance after birth. However, in persistent pulmonary hypertension of the newborn (PPHN) NO-mediated dilation is dysfunctional. GTP-cyclohydrolase 1 (GTP-CH1) is the rate-limiting enzyme for the biosynthesis of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) an essential cofactor for nitric oxide synthase (NOS) activity. Suboptimal levels of BH4 may result in NOS uncoupling and the subsequent generation of harmful superoxide anions. We therefore investigated the functional effects of supplementing BH4 and/or a superoxide dismutase mimetic (MnTMPyP) in porcine intrapulmonary arteries from normal animals and from a porcine model of PPHN. We investigated whether any functional effects of BH4 could be explained by changes in GTP-CH1 expression. Supplementation of BH4 significantly improved endothelium-dependent relaxations in arteries from 3- and 14-d-old healthy animals, whereas no effect was seen in vessels from younger animals and adults. GTP-CH1 protein expression was lowest at 3 and 14 d, suggesting a rate limitation of BH4 at this time. BH4 supplementation alone did not improve the relaxant response to acetylcholine in arteries obtained in a porcine model of PPHN. Furthermore, GTP-CH1 protein expression was normal for age. However, co-treatment with both BH4 and MnTMPyP restored endothelial function. GTP-CH1 is developmentally regulated in the pulmonary vasculature of neonates and this results in a functionally significant limitation of BH4. Although GTP-CH-1/BH4 levels alone do not explain the profound endothelial dysfunction seen in PPHN, increasing NO bioavailability by supplementing BH4 and quenching superoxide may prove to be therapeutically beneficial.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641207     DOI: 10.1203/01.pdr.0000219301.19958.a0

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

Review 1.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

Review 2.  Therapeutic approaches using nitric oxide in infants and children.

Authors:  Robin H Steinhorn
Journal:  Free Radic Biol Med       Date:  2011-01-13       Impact factor: 7.376

Review 3.  In Development-A New Paradigm for Understanding Vascular Disease.

Authors:  Nicholas A Flavahan
Journal:  J Cardiovasc Pharmacol       Date:  2017-05       Impact factor: 3.105

4.  Pressure-induced maturation of endothelial cells on newborn mouse carotid arteries.

Authors:  Sheila Flavahan; Mansoor M Mozayan; Isa Lindgren; Nicholas A Flavahan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-24       Impact factor: 4.733

5.  Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension.

Authors:  Kathryn N Farrow; Satyan Lakshminrusimha; William J Reda; Stephen Wedgwood; Lyubov Czech; Sylvia F Gugino; Jonathan M Davis; James A Russell; Robin H Steinhorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-09-12       Impact factor: 5.464

6.  Effects of tetrahydrobiopterin oral treatment in hypoxia-induced pulmonary hypertension in rat.

Authors:  Bahaa N Francis; Ashley Hale; Keith M Channon; Martin R Wilkins; Lan Zhao
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.